Roche names new Foundation Med chief; Akorn shares dip on FDA warning letter; Zai Lab advances pivotal PARP study
→ Six months after Roche paid $2.4 billion to buy complete control of Foundation Medicine the pharma giant is following up by putting its …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
